466 related articles for article (PubMed ID: 19949401)
21. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
Kaitin KI; DiMasi JA
Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
[TBL] [Abstract][Full Text] [Related]
22. Decline in the Development of New Anesthetics.
Vlassakov KV; Kissin I
Trends Pharmacol Sci; 2016 May; 37(5):344-352. PubMed ID: 26922254
[TBL] [Abstract][Full Text] [Related]
23. A brief history of generic substitution in the USA.
Sullivan CG
Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
[No Abstract] [Full Text] [Related]
24. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
25. The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164339
[TBL] [Abstract][Full Text] [Related]
26. Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A; Lauterio TJ; Davis MW
Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
Tay-Teo K; Ilbawi A; Hill SR
JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
29. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications.
Berndt ER; Cockburn IM; Grépin KA
Pharmacoeconomics; 2006 Dec; 24 Suppl 2():69-86. PubMed ID: 23389490
[TBL] [Abstract][Full Text] [Related]
30. Post-approval fate of pharmaceutical companies.
Kinch MS
Drug Discov Today; 2015 Feb; 20(2):170-4. PubMed ID: 25448760
[TBL] [Abstract][Full Text] [Related]
31. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study.
Schwartz JL
N Engl J Med; 2016 Nov; 375(21):2015-2017. PubMed ID: 27959733
[No Abstract] [Full Text] [Related]
32. [Yesterday, today and tomorrow: urology and the pharmaceutical industry: successful team work for the benefit of the patient].
Cardinal A
Urologe A; 2006 Sep; 45 Suppl 4():43-4. PubMed ID: 16955326
[No Abstract] [Full Text] [Related]
33. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
34. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
35. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
36. Did Medicare Induce Pharmaceutical Innovation?
Acemoglu D; Cutler D; Finkelstein A; Linn J
Am Econ Rev; 2006 May; 96(2):103-7. PubMed ID: 29131561
[No Abstract] [Full Text] [Related]
37. Failing the public health--rofecoxib, Merck, and the FDA.
Topol EJ
N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
[No Abstract] [Full Text] [Related]
38. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
39. Drug development and FDA approval, 1938-2013.
Darrow JJ; Kesselheim AS
N Engl J Med; 2014 Jun; 370(26):e39. PubMed ID: 24963591
[No Abstract] [Full Text] [Related]
40. Raising the game.
Nat Biotechnol; 2008 Feb; 26(2):137. PubMed ID: 18259155
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
